USBio Logo

145715 Macrophage inflammatory protein 3 beta, Recombinant, Rat, aa26-108, CF (CCL19, MIP-3 beta, Mip-3beta, ELC, CKbeta-11, Scya19, Exodus-3) CAS:

Specifications
References
Grade
Highly Purified
Accession Number
NP_001102131
Molecular Weight
10
EU Commodity Code
30021019
Shipping Temp
Blue Ice
Storage Temp
-20°C
BSA Free
Yes
Notes
BSA Free

CCL19 (also known as Mip-3beta, ELC, CKbeta-11, Scya19 and Exodus-3) is a 9kD secreted member of the CC family of chemotactic cytokines (1-4). Cells known to express CCL19 are limited in number, and include activated monocytes (5), stromal cells in nodal T zones (6), CD8+ dendritic cells (DC) (6), vascular endothelial cells (7), visceral smooth muscle and mast cells (8), and thymic stromal cells (9). Rat CCL19 is synthesized as a precursor that is 1108 amino acids (aa) in length. The precursor contains a 25 aa signal sequence plus an 83 aa mature region (aa 26-108) (10). The signature CC chemokine motif occurs at Cys33Cys34 and there are no potential N­linked glycosylation sites. It is unclear if rat CCL19 forms homodimers. Mature rat CCL19 shares 72% and 89% aa sequence identity with human and mouse CCL19, respectively (3, 4, 10). CCL19 is known to bind to CCR7 (3, 4), CCLR2/CRAM (L-CCR in rodent) (11, 12, 13) and CCX­CKR (14), with the last two receptors representing scavenger, or chemokine-sink receptors. Cells expressing the signaling receptor (CCR7) are varied in type, and include CD56+ NK cells (15), naïve CD4+ T and activated B cells (4), mature bone marrow-derived dendritic and Langerhans cells (16), Collagen I+III+Fibronectin+ fibrocytes (17) and CD4+ Tregs (9). Upon CCR7 engagement, CCL19 has a number of documented effects. In the case of the DC, it reportedly induces DC cytoplasmic extension, increases endocytic activity, protects DC from apoptosis, increases the speed of DC migration, and promotes its secretion of cytokines (18). Notably, while CCL19 is a potent chemoattractant, this activity seems to be dependent upon concomitant EP2 and EP4 receptor activation, coupled to an increase in the presence of NO (18). CCL19 is perhaps best known as a secondary lymphoid organ homing molecule for naïve lymphocytes. Here, a CCL21 gradient is believed to first draw naïve CD4+ T cells into tissue lymphatic channels. At this point, CCL19 becomes predominate, amplifying chemoattraction and inducing an up­regulation of EDG1, a receptor for sphingosine-1 phosphate/S1P. Upon entry into the lymph node, the naïve CD4+ T cells encounters APCs/DCs which may, or may not, be presenting compatible antigen. If so, an immunological synapse is generated and the activated T cell remains in the node. If not, the continuous CCL19:CCR7 interaction results in an internalization of CCR7, with a resultant loss of chemoattractive activity. The activity of up-regulated EDG1 now predominates, and naïve T cells migrate out of the node, and into the blood in response to a constitutive gradient of S1P. The exact source of S1P is unclear, but may represent a natural difference between plasma and tissue levels (19, 20).

Source
Recombinant protein corresponding to aa26-108 from rat CCL19/MIP-3 beta, expressed E. coli.
Molecular Weight
~10kD
Endotoxin
<0.01EU/1ug (LAL method)
Storage and Stability
Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O or PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Source
Recombinant, E. coli
Purity
~95% (SDS-PAGE)
Concentration
~0.1mg/ml (after reconstitution)
Form
Supplied as a lyophilized powder in PBS. BSA free. Reconstitute in 250ul PBS.
Important Note
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
References
1. Sharma, M. (2010) Crit. Rev. Biotechnol. 30:1. 2. Blanchet, X. et al. (2012) Front. Immunol. 3:175. 3. Yoshida, R. et al. (1997) J. Biol. Chem. 272:13803. 4. Ngo, V.N. et al. (1998) J. Exp. Med. 188:181. 5. Rossi, D.L. et al. (1997) J. Immunol. 158:1033. 6. Luther, S.A. et al. (2000) Proc. Natl. Acad. Sci. USA 97:12694. 7. Alt, C. et al. (2002) Eur. J. Immunol. 32:2133. 8. Kaur, D. et al. (2006) Am. J. Respir. Crit. Care Med. 174:1179. 9. Takamura, K. et al. (2007) J. Immunol. 179:5897. 10. Leick, M. et al. (2009) Immunology 129:536. 11. Yoshimura, T. & J.J. Oppenheim (2011) Exp. Cell Res. 317:674. 12. Shimida, T. et al. (1998) FEBS Lett. 425:490. 13. Comerford, I. et al. (2006) Eur. J. Immunol. 36:1904. 14. Maghazachi, A.A. (2010) Curr. Top. Microbiol. Immunol. 341:37. 15. Yanagihara, S. et al. (1998) J. Immunol. 161:3096. 16. Abe, R. et al. (2001) J. Immunol. 166:7556. 17. Sanchez­Sanchez, N. et al. (2006) J. Immunol. 176:5153. 18. Shannon, L.A. et al. (2012) J. Biol. Chem. 287:11656. 19. Schwab, S.R. & J.G. Cyster (2007) Nat. Immunol. 8:1295.
USBio References
No references available
Pricing
Order
Proceed to Checkout
Cart Summary
ProductSizeListYour PriceQtyExt Price
Subtotal:Subtotal:
Subtotal:Subtotal:
Total Coupon Savings:Total Coupon Savings:()
Your cart is currently empty.
- Coupon Code
Recently Viewed
  • Contact Us

    Visit our technical library or contact our support staff to answer your questions.

    Telephone:
    1-800-520-3011

    Library | Contact

    Distributors

    For customers outside of the United States, please use one of our many distributors.

    View Distributors

    Payment Methods

    We accept the following payment methods as well as pay-by-invoice.

    MasterCard Visa PayPal
    © 2023-2024 United States Biological - All Rights Reserved